Sign In
Buy NVTA
$0.0190
+0 (+0%)
At Close: May 13, 2024
Orchard Therapeutics' (ORTX) CEO Bobby Gaspar on Q1 2020 Results - Earnings Call Transcript
07:36am, Saturday, 09'th May 2020
Orchard Therapeutics plc (NASDAQ:ORTX) Q1 2020 Earnings Conference Call May 07, 2020 8:00 AM ET Company Participants Renee Leck – Director-Investor Relations Bo
Invitae Readies Telemedicine Marketing Blitz as Testing Volumes Fall 50%
01:00pm, Friday, 08'th May 2020
The company thinks a post-pandemic world will appreciate the need for genetic information more than before, but Invitae must navigate uncertainty in the meantime.
Invitae makes it easier for consumers to access medical genetic tests in Canada
11:30am, Thursday, 07'th May 2020
SAN FRANCISCO , May 7, 2020 /CNW/ -- Invitae (NVTA), a leader in medical genetics, today announced the expansion of online ordering for its high-quality medical genetic tests to Canada . Through
Invitae Corp (NVTA) Q1 2020 Earnings Call Transcript
04:31pm, Wednesday, 06'th May 2020
Ladies and gentlemen, thank you for standing by and welcome to the Invitae's First Quarter 2020 Financial Results Conference Call. Joining us today are Sean George, our CEO; Shelly Guyer, our CFO; Le
Edited Transcript of NVTA earnings conference call or presentation 5-May-20 8:30pm GMT
03:09pm, Wednesday, 06'th May 2020
Q1 2020 Invitae Corp Earnings Call
Invitae Posts Mixed Q1 Results, Reducing Cash Burn in the Wake of the COVID-19 Pandemic
11:00am, Wednesday, 06'th May 2020
The medical genetics company achieved record-high testing volume growth in Q1. But the COVID-19 outbreak began taking a toll late in the quarter.
Invitae (NVTA) Reports Q1 Loss, Tops Revenue Estimates
11:05pm, Tuesday, 05'th May 2020
Invitae (NVTA) delivered earnings and revenue surprises of 4.76% and 3.45%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Invitae Reports More Than $64 Million in Revenue Driven by More Than 154,000 Samples Accessioned in the First Quarter of 2020
08:05pm, Tuesday, 05'th May 2020
Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced financial and operating results for the first quarter ended March 31, 2020.
The Coronavirus Pandemic Will Test Invitae's Telemedicine Ambitions
10:36am, Tuesday, 05'th May 2020
Invitae wants to provide medical-grade genetic testing to the masses. Is the business ready for the first big test?
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks hitting 52-week highs May 5.)
Arcturus Therapeutics Ltd (...
Genetic Testing Likely to Drive Invitae's (NVTA) Q1 Earnings
01:34pm, Monday, 04'th May 2020
Invitae's (NVTA) genetic testing business is expected to have gained from expansion of biopharma partnerships in Q1.
The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace
12:00am, Sunday, 03'rd May 2020
Biotech stocks started last week on a strong note but the upward momentum slowed through the week. The week saw a slew of earnings from big pharma names, including Merck...
InVitae (NYSE:NVTA) Rating Lowered to Buy at ValuEngine
06:24am, Saturday, 02'nd May 2020
InVitae (NYSE:NVTA) was downgraded by stock analysts at ValuEngine from a “strong-buy” rating to a “buy” rating in a report released on Friday, ValuEngine reports. Other equities research anal
Will Invitae Corporation Continue to Surge Higher?
11:01am, Friday, 01'st May 2020
As of late, it has definitely been a great time to be an investor Invitae Corporation
New York, April 30, 2020 -- Reportlinker.com announces the release of the report "Global Hematologic Malignancies Testing Market: Focus on Product, Disease, Technology, End.
